血液系统恶性肿瘤细胞免疫治疗的研究进展

doi:10.11904/j.issn.1002-3070.2016.01.013

摘要/Abstract

摘要： 近年来,血液系统恶性肿瘤的治疗虽然取得了很大进展,但多数患者最终仍会复发并遭受化疗或放疗引起的严重副作用。因此,过继性细胞免疫治疗作为一种耐受良好、安全有效的创新性疗法应运而生。它是将体外扩增或处理后的免疫效应细胞回输到患者体内杀灭肿瘤或控制复发的一种疗法,被积极应用于各类血液系统恶性肿瘤的治疗,并取得了显著的疗效,为更多的复发难治性血液病患者带来了希望。

关键词: 血液系统恶性肿瘤, 细胞免疫治疗, CIK细胞, NK细胞, CART

Abstract: In recent years,considerable progress has been made in the treatment of hematologic malignancies.However,most patients will eventually relapse and suffer from severe side effects caused by chemotherapy or radiation.Thus,as a well tolerated,safe,effective and innovative therapy,adoptive cellular immunotherapy emerges at this very moment.This therapy can kill tumors or control recurrence by reinfusing the in vitro amplificated or treated immune effective cells into the patients.It has been actively used in the treatment of various hematological malignancies and achieved significant effects,which brings hope for more and more patients with relapsed or refractory hematological diseases.

Key words: Hematological malignancies, Cellular immunotherapy, CIK cells, NK cells, CART

中图分类号:

R730.51

黄娟娟, 王雯欣综述, 曹峰林审校. 血液系统恶性肿瘤细胞免疫治疗的研究进展[J]. 实用肿瘤学杂志, 2016, 30(1): 61-65.

HUANG Juanjuan, WANG Wenxin, CAO Fenglin. Research progress of cellular immunotherapy for hematological malignancies[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(1): 61-65.

参考文献

1 Sangiolo D,Martinuzzi E,Todorovic M,et al.Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer(CIK)cells:implications for their infusion across major HLA barriers[J].Int Immunol,2008,20(7):841-848.
2 Kornacker M,Moldenhauer G,Herbst M,et al.Cytokine-induced killer cells against autologous CLL:direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma[J].Int J Cancer,2006,119(6):1377-1382.
3 Pievani A,Borleri G,Pende D,et al.Dual-functional capability of CD3+CD56+CIK cells,a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity[J].Blood,2011,118(12):3301-3310.
4 Wang Y,Bo J,Dai HR,et al.CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo[J].Exp Hematol,2013,41(3):241-52.
5 Linn YC,Yong HX,Niam M,et al.A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission[J].Cytotherapy,2012,14(7):851-859.
6 Lu XC,Yang B,Yu RL,et al.Clinical study of autologous cytokine-induced killer cells for the treatment of elderly patients with diffuse large B-cell lymphoma[J].Cell Biochem Biophys,2012,62(1):257-265.
7 Cai LL,Yang Y,Yang B,et al.Short-term curative efficacy of autologous cytokine induced killer cells combined with low-dose IL-2 regimen containing immune enhancement by thymic peptide in elderly patients with B-cell chronic lymphocytic leukemia(in Chinese)[J].Zhongguo Shi Yan Xue Ye Xue Za Zhi,2012,20(3):564-570.
8 Yang B,Wang J,Cai LL,et al.Treatment of multiple solitary plasmacytomas with cytokine-induced killer cells[J].Cytotherapy,2014,16(2):278-284.
9 Yang B,Lu XC,Yu RL,et al.Repeated transfusions of autologous cytokine-induced killer cells for treatment of haematological malignancies in elderly patients:A pilot clinical trial[J].Hematol Oncol,2012,30(3):115-122.
10 Thanendrarajan S,Nowak M,Abken H,et al.Combining cytokine-induced killer cells with vaccination in cancer immunotherapy:More than one plus one[J].Leuk Res,2011,35(9):1136-1142.
11 Zheng Z,Yuna Z,Huimin Z,et al.Clinical study of DC-CIK(dendritic cells and cytokine-induced killer cells)eliminate minimal residual leukemia[J].Blood,2013,122(6):1450-1461.
12 Zhou DF,Zhai LN,Pan F,et al.Co-cultured dendritic cell and cytokine-induced killer cell adaptive immunotherapy for treating of childhood acute leukemia[J].Pediatric Clin Practical Mag,2012,27(3):166-169.
13 Zhong GC,Yan B,Sun Y,et al.Clinical efficacy of immunotherapy of dendritic cell and cytokine-induced killer cell combined with chemotherapy for treatment of multiple myeloma(in Chinese)[J].Zhonghua Xue Ye Xue Za Zhi,2012,33(12):1000-1003.
14 Benjamin J,Laport GG,Tate K,et al.Early infusion of donor-derived CIK cells as consolidative immunotherapy following non-myeloablative allogeneic transplantation:safety and feasibility[J].Blood,2013,122(6):899-912.
15 Zhou X,Zhu J,Sun H,et al.Family haploidentical donor-derived cytokine-induced killer cell biotherapy combined with bortezomib in two patients with relapsed multiple myeloma in a non-allogeneic transplant setting[J].Leukemia Lymphoma,2013,54(1):209-211.
16 Linn YC,Niam M,Chu S,et al.The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies[J].Bone Marrow Transplant,2012,47(7):957-966.
17 Knorr DA,Bachanova V,Verneris MR,et al.Clinical utility of natural killer cells in cancer therapy and transplantation[J].Semin Immunol,2014,26(2):161-172.
18 Cheng M,Chen Y,Xiao W,et al.NK cell-based immunotherapy for malignant diseases[J].Cell Mol Immunol,2013,10(3):230-252.
19 Venstrom JM,Dupont B,Hsu KC,et al.Donor activating KIR2DS1 in leukemia[J].N Engl J Med,2014,371(21):2042-2051.
20 Zhang J,Basher F,Wu JD,et al.NKG2D ligands in tumor immunity:two sides of a coin[J].Front Immunol,2015,6:97.
21 Parkhurst MR,Riley JP,Dudley ME,et al.Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression[J].Clin Cancer Res,2011,17(19):6287-6297.
22 Bachanova V,Miller JS.NK cells in therapy of cancer[J].Crit Rev Oncog,2014,19(1-2):133-141.
23 Miller JS,Rooney CM,Curtsinger J,et al.Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration:implications for clinical therapy[J].Biol Blood Marrow Transplant,2014,20(8):1252-1257.
24 Cooley S,Weisdorf DJ,Guethlein LA,et al.Donor killer cell Ig-like receptor B haplotypes,recipient HLA-C1,and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia[J].J Immunol,2014,192(10):4592-4600.
25 Benjamin JE,Gill S,Negrin RS.Biology and clinical effects of natural killer cells in allogeneic transplantation[J].Curr Opin Oncol,2010,22(2):130-137.
26 Curti A,Ruggeri L,D′Addio A,et al.Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients[J].Blood,2011,118(12):3273-3279.
27 Shi J,Tricot G,Szmania S,et al.Infusion of haplo-identical killer immunoglobulin-like receptor ligand mis-matched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation[J].Br J Haematol,2008,143(5):641-653.
28 Kalos M,June CH.Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology[J].Immunity,2013,39(1):49-60.
29 Porter DL,Levine BL,Kalos M,et al.Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia[J].N Engl J Med,2011,365(8):725-733.
30 Grupp SA,Kalos M,Barrett D,et al.Chimeric antigen receptor-modified T cells for acute lymphoid leukemia[J].N Engl J Med,2013,368(16):1509-1518.
31 Davila ML,Riviere I,Wang X,et al.Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia[J].Sci Transl Med,2014,6(224):224-225.
32 Cruz CR,Micklethwaite KP,Savoldo B,et al.Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant:a phase 1 study[J].Blood,2013,122(17):2965-2973.
33 Lee DW,Gardner R,Porter DL,et al.Current concepts in the diagnosis and management of cytokine release syndrome[J].Blood,2014,124(2):188-195.

[1]	张丽坤,曹峰林. 自体细胞因子诱导的杀伤细胞治疗肺癌患者的临床疗效观察[J]. 实用肿瘤学杂志, 2015, 29(4): 342-346.
[2]	鲁祥石,宋传健,崔静,秦莉,梅芬,张艳桥,赵娟,吕慧敏,张本宁. 应用晚期乳腺癌患者外周血单个核细胞体外增殖诱导新型CIK细胞的实验研究[J]. 实用肿瘤学杂志, 2014, 28(5): 391-395.
[3]	王茜, 张月桂, 黄孙卉, 卢珊, 李凤琴. 自体CIK细胞治疗恶性肿瘤的护理[J]. 实用肿瘤学杂志, 2011, 25(6): 561-563.
[4]	王艳辉, 张南征, 陈复兴, 刘军权, 周忠海, 孙蕾清. 自然杀伤细胞对小鼠HepS肝癌移植瘤的抑制作用研究[J]. 实用肿瘤学杂志, 2011, 25(4): 319-324.
[5]	刘芳, 于雁, 张华. 化疗联合CIK细胞回输治疗老年晚期非小细胞肺癌成本-效果分析[J]. 实用肿瘤学杂志, 2011, 25(4): 336-339.
[6]	赵娟, 张艳桥. CIK细胞治疗胃癌的研究现状及应用进展[J]. 实用肿瘤学杂志, 2011, 25(1): 22-25.
[7]	徐京京, 张艳桥. DC-CIK细胞在乳腺癌治疗中的研究现状[J]. 实用肿瘤学杂志, 2011, 25(1): 26-28.
[8]	蓝毓滨;王志华;张彦. 无血清培养基对体外激活的A-NK细胞的支持作用[J]. 实用肿瘤学杂志, 2005, 19(06): 405-407.
[9]	李雪梅;孙抒;王建光;杨万山. CIK细胞对 MGC-803胃癌细胞株的诱导凋亡作用[J]. 实用肿瘤学杂志, 2004, 18(06): 413-416.
[10]	宁忠华;徐爱乡;华东. 血小板对外周血纯化、扩增的NK细胞杀伤K562细胞的影响[J]. 实用肿瘤学杂志, 2004, 18(02): 130-134.
[11]	李娟;罗绍凯;黎军和;赵莹. 5-HT3受体拮抗剂在血液系统恶性肿瘤患者化疗止吐中的应用[J]. 实用肿瘤学杂志, 2003, 17(03): 224-226.
[12]	李娟;罗绍凯;彭爱华. 血液系统恶性肿瘤患者化疗后感染的防治[J]. 实用肿瘤学杂志, 2001, 15(03): 207-209.